Gene · 9133
Papers2,908
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,908
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4. | Phytother Res | 2026 | 41858177 | PubTator, text mining | PubMed |
| AURKB as a key driver of esophageal cancer progression: Molecular mechanisms and potential nursing implications based on multi-omics analysis. | Medicine (Baltimore) | 2026 | 41824870 | PubTator, text mining | PubMed |
| Proteomics and Lipidomics Analysis Reveal That Membrane Remodeling and Extracellular Matrix Alterations Are Crucial for Cisplatin Resistance in Triple-Negative Breast Cancer. | J Proteome Res | 2026 | 41823008 | PubTator, text mining | PubMed |
| SMC4/SMAD3/NF-κB axis drives cervical cancer progression and radioresistance via DNA damage repair and immune modulation. | J Transl Med | 2026 | 41803949 | PubTator, text mining | PubMed |
| PVT1 lincRNA signals an androgen-dependent transcriptional activation program of oncogenes in prostate cancer cells. | Int J Cancer | 2026 | 41792045 | PubTator, text mining | PubMed |
| Paired-Box (PAX) Gene Signatures as a Biomarker of Breast Cancer Progression. | Int J Mol Sci | 2026 | 41752124 | PubTator, text mining | PubMed |
| KIF18B Is Essential for Lung Adenocarcinoma Progression Through the E2F Transcriptional Network. | Int J Mol Sci | 2026 | 41751942 | PubTator, text mining | PubMed |
| Enhancing Cancer Therapy with Hyperthermia: Synergistic Effects with Natural Compounds and Conventional Treatments. | Int J Mol Sci | 2026 | 41751791 | PubTator, text mining | PubMed |
| Identification of Key Genes Regulating Body Weight in Qingyuan Partridge Chickens During Development Using RNA-Sequence Analysis. | Genes (Basel) | 2026 | 41751563 | PubTator, text mining | PubMed |
| Comprehensive analysis of mitophagy-related genes reveals prognostic signatures in breast cancer: based on immune landscapes and treatment target predict. | Front Immunol | 2026 | 41727445 | PubTator, text mining | PubMed |
| Charting the multilevel molecular response to palbociclib in ER-positive breast cancer. | NAR Cancer | 2026 | 41710088 | PubTator, text mining | PubMed |
| Countervailing effects of cyclin isoforms A and B during mitosis. | bioRxiv | 2026 | 41684933 | PubTator, text mining | PubMed |
| Snail1 Induced Suppression of Proliferation via EGR1, FOXO1, and CEPBγ Creates a Vulnerability for Targeting Apoptotic and Cellular Senescence Pathways. | Cancers (Basel) | 2026 | 41681982 | PubTator, text mining | PubMed |
| Analysis of the molecular mechanism underlying di(2-ethylhexyl) phthalate-induced bladder carcinogenesis via network toxicology and molecular docking approaches: An observational study. | Medicine (Baltimore) | 2026 | 41650055 | PubTator, text mining | PubMed |
| NDC80 kinetochore complex component is a potential molecular target of adenoid cystic carcinoma. | Oncol Lett | 2026 | 41626143 | PubTator, text mining | PubMed |
| ESRRG downregulation in early spontaneous abortion induces mitochondrial damage, leading to impaired trophoblast function. | Ann Med | 2026 | 41623023 | PubTator, text mining | PubMed |
| The miR-29b Byproduct MIRTX Shows Superior Anti-tumor Activity, Compared to miR-29b-3p, in Pancreatic Cancer Cells. | Anticancer Res | 2026 | 41617446 | PubTator, text mining | PubMed |
| HNRNPF Increases MAF and CCNB2 Levels To Promote Cancer Cell Stemness and Progression of Pancreatic Ductal Adenocarcinoma. | Stem Cell Rev Rep | 2026 | 41612011 | PubTator, text mining | PubMed |
| Transcriptomic insights into the immune dynamics of wild-type mice challenged with SARS-CoV-2 Beta variant. | Lab Anim Res | 2026 | 41606700 | PubTator, text mining | PubMed |
| Integrated Transcriptomics and Targeted Metabolomics Approaches: Comparative Analysis of the Ileum in Neonatal Piglets with Different Birth Weight. | Animals (Basel) | 2026 | 41594403 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9133/papers?page=2